The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements
12:15 MIN
- CIDP
Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
15:18 MIN
- CIDP
- GBS
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy
8:25 MIN
- CIDP
Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
15:31 MIN
- CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
NOW PLAYING
12:15
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength...
Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
NOW PLAYING
15:18
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
NOW PLAYING
8:25
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Th...
Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.
NOW PLAYING
15:31
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
Our Experts on CIDP
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
- CIDP
- GBS
Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan.
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
- CIDP
Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Carol L. Koski, MD
GBS/CIDP Foundation International
Carol L. Koski, MD
GBS/CIDP Foundation International
- CIDP
- GBS
Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
- CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Slides & Posters about CIDP
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements
PDF | 2.35 MB
IgG Levels and Wear Off Reflect Administration and Outcome
PDF | 1.5 MB
Pathogenesis and Mechanism of Action of Inflammatory Neuropathies
PDF | 680 KB
CIDP Assessment Tools: Grip Strength
PDF |
Back to Top